Screener
Jazz Pharmaceuticals JAZZ Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Income (loss) from operations | 336.6 | (55.9) |
| Interest expense, net | (39.9) | (53.7) |
| Foreign exchange gain (loss) | 2.5 | (0.2) |
| Income (loss) before income tax expense (benefit) and equity in loss of investees | 299.2 | (109.8) |
| Income tax expense (benefit) | 6.1 | (17.8) |
| Equity in loss of investees | — | 0.5 |
| Net income (loss) | $293.1 | $(92.5) |
| Net income (loss) per ordinary share: |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's pre-tax income?
- Jazz Pharmaceuticals (JAZZ) reported pre-tax income of $299.2M in Q1 2026.
- How has Jazz Pharmaceuticals's pre-tax income changed year-over-year?
- Jazz Pharmaceuticals's pre-tax income increased by 372.5% year-over-year, from -$109.8M to $299.2M.
- What is the long-term trend for Jazz Pharmaceuticals's pre-tax income?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's pre-tax income has grown at a 60.9% compound annual growth rate (CAGR), from -$112.84M to $470.35M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Jazz Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude